Core Viewpoint - The company Kintor Pharmaceutical (02171) anticipates a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of its drug Zeworkiobulin and the acceptance of the new drug application for Shurikiobulin by the National Medical Products Administration (NMPA) [1] Financial Performance - The expected net loss for the reporting period is projected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the fiscal year ending December 31, 2024 [1] - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the fiscal year ending December 31, 2024 [1] Factors Influencing Loss Reduction - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zeworkiobulin in mainland China [1] - Impact of foreign exchange fluctuations [1] - Significant reduction in research and development expenses for both Zeworkiobulin and Shurikiobulin [1]
科济药业-B(02171)发盈警 预期2025年取得净亏损同比减少至不超过约1.2亿元